Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-01T11:14:48.088Z Has data issue: false hasContentIssue false
  • English
  • Français

Thioproperazine in Chronic Schizophrenia

Published online by Cambridge University Press:  29 January 2018

A. Hordern ,
A. King ,
N. F. Holt ,
J. Collins  and
J. Toussaint
A. Hordern
Affiliation:
Department of Mental Hygiene, State of California, Sacramento, California, U.S.A
A. King
Affiliation:
Neurosurgical Unit, Mont Park Hospital, Victoria, Australia
N. F. Holt
Affiliation:
Mental Health Research Institute, Melbourne, Victoria, Australia
J. Collins
Affiliation:
Hobson Park Hospital, Traralgon, Victoria, Australia
J. Toussaint
Affiliation:
Mont Park Hospital, Victoria, Australia
Get access Rights & Permissions [Opens in a new window]

Extract

Despite the advent of the stimulant phenothiazines—effective, sometimes, when older dimethyl compounds fail—a proportion of chronic schizophrenics continue to resist treatment with both types of drug, and also fail to respond to intensive nursing regimes designed to combat the effects of institutionalization. These patients constitute a major therapeutic problem.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 110 , Issue 467 , July 1964 , pp. 531 - 539
Copyright
Copyright © Royal College of Psychiatrists, 1964 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Annesley, P. P., and Mant, A. K. (1962). “A fatal reaction to thioproperazine.” Brit. med. J., i, 233.Google Scholar
Annotation, (1961a). “Thioproperazine.” Lancet, ii, 698.Google Scholar
Annotation, (1961b). “Extrapyramidal effects of tranquillizers.” Ibid., ii, 918–919.Google Scholar
Arnold, O. H., and Hoff, H. (1961). “The role of biological treatment in comprehensive psychiatric management.” In: Recent Advances in Biological Psychiatry. Vol. 3. (Edited by Wortis, Joseph.) New York: Grune and Stratton, pp. 12–29.Google Scholar
Ayd, F. J. (1961). “Neuroleptics and extrapyramidal reactions in psychiatric patients.” In: Extrapyramidal System and Neuroleptics. (Edited by Bordeleau, J. M.) Montreal: Editions Psychiatriques, pp. 355–363.Google Scholar
Barsa, J. A., and Saunders, J. C. (1961). “Fluphenazine use with chronic psychotic patients.” Dis. New. Syst., 22, 211–212.Google Scholar
Bordeleau, J. (Ed.) (1961). Extrapyramidal System and Neuroleptics. Montreal: Editions Psychiatriques.Google Scholar
Cole, J. O., and Clyde, D. J. (1961). “Extrapyramidal side-effects and clinical response to the phenothiazines.” In: Extrapyramidal System and Neuroleptics, pp. 469–478. Vide supra .Google Scholar
Cramond, W. A. (1962). “Thioproperazine.” Lancet, i, 592–593.CrossRefGoogle Scholar
Delay, J., and Deniker, P. (1961). “Apport de la clinique à la connaissance de l'action des neuro leptiques.” In: Extrapyramidal System and Neuroleptics, pp. 301–327. Vide supra .Google Scholar
Delay, J., and Deniker, P. Delay, J., and Deniker, P. Beek, H., Barande, R., and Eurieult, M. (1959). “Syndromes neurologiques experimentaux et thérapeutique psychiatrique. I: Effets neurologiques d'un nouveau neuroleptique majeur, le 7843 R.P. Étude polygraphique.” Presse Méd., 67, 123–126, 201–203.Google Scholar
Denber, H. C. B. (1961). “Psychodynamic effects of the drug-induced extrapyramidal reaction on ward social structure.” In: Extrapyramidal System and Neuroleptics, pp. 535–545. Vide supra .Google Scholar
Denber, H. C. B. Rajotte, P., and Kauffman, D. (1959). “Clinical experiences with a new phenothiazine.” Amer. J. Psychiat., 115, 1116–1117.Google Scholar
Denber, H. C. B. Rajotte, P., and Kauffman, D. Denber, H. C. B. Rajotte, P., and Kauffman, D. Denber, H. C. B. Rajotte, P., and Kauffman, D. (1960). “Report on a phenothiazine of high clinical potency.” Dis. New. Syst., 21, 39–41.Google Scholar
Denham, J. (1961). “The implications of extrapyramidal symptoms in the treatment of schizophrenia.” In: Extrapyramidal System and Neuroleptics, pp. 449–452. Vide supra .Google Scholar
Denham, J. and Carrick, D. J. E. L. (1961). “Therapeutic value of thioproperazine and the importance of the associated neurological disturbances.” J. Ment. Sci., 107, 326–345.Google Scholar
Deniker, P. (1960). “Experimental neurological syndromes and the new drug therapies in psychiatry.” Comprehen. Psychiat., i, 92–102.Google Scholar
Freyhan, F. A. (1961). “The relationship of drug-induced neurological phenomena to therapeutic outcome.” In: Extrapyramidal System and Neuroleptics, pp. 483–486. Vide supra .Google Scholar
Goldman, D. (1961). “Parkinsonism and related phenomena from administration of drugs: their production and control under clinical conditions and possible relation to therapeutic effect.” In: Extrapyramidal System and Neuroleptics, pp. 453–464. Vide supra .Google Scholar
Haase, H. J. (1961). “Extrapyramidal modification of fine movements…. a ‘conditio sine qua non’ of the functional therapeutic action of neuroleptic drugs.” In: Extrapyramidal System and Neuroleptics, pp. 329–353. Vide supra .Google Scholar
Hankoff, L. D., Mendelsohn, F. S., and Paley, H. M. (1960). “Fluphenazine treatment in a receiving house setting.” Dis. New. Syst., 21, 467–472.Google Scholar
Holt, J. P., and Wright, E. R. (1961). “Clinical evaluation of fluphenazine in the treatment of psychotic patients.” Ibid., 22, 513–519.Google Scholar
Hordern, A. (1961). “Psychiatry and the tranquillizers.” New Eng. J. Med., 265, 584–588, 634–638.Google Scholar
Hordern, A. Somerville, D. M., and Krupinski, J. (1962). “Does chronic schizophrenia respond to a combination of a neuroleptic and an antidepressant?” J. New. Ment. Dis., 134, 361–376.Google Scholar
Howell, R. J., Brown, H. M., and Beaghler, H. E. (1961). “A comparison of fluphenazine, trifluoperazine and a placebo in the context of an active treatment unit.” Ibid., 132, 522–530.Google Scholar
Kinross-Wright, J., Rowell, R. C., and Otero, M. J. (1962). “Fluphenazine in treatment of chronic schizophrenia.” Dis. New. Syst., 23, 152–155.Google Scholar
Kline, N. S., and Mettler, F. A. (1961). “The extrapyramidal system and schizophrenia.” In: Extrapyramidal System and Neuroleptics, pp. 487–491. Vide supra .Google Scholar
Kruse, W. (1961). “The relationship between anti-hallucinatory effect and extrapyramidal symptoms induced by fluphenazine (a study in 40 chronic schizophrenics).” Current Therap., Res. 3, 19–21.Google Scholar
Kurland, A. A., Hanlon, T. E., and Ota, K. Y. (1961). “Fluphenazine in the treatment of the hospitalized psychiatric patient.” Dis. New. Syst., 22, 339–343.Google Scholar
Lorr, M. (1953). “The multidimensional scale for rating psychiatric patients; Hospital form 1.” U.S.V.A. Tech. Bull., T.B. 19–507. Washington, D.C. Google Scholar
Lortie, G. (1961). “The importance and the meaning of drug-induced extrapyramidal reactions to the psychotic patient.” In: Extrapyramidal System and Neuroleptics, pp. 553–561. Vide supra .Google Scholar
MacLeod, E. C., and Moffat, J. (1963). “Continuous thioproperazine. A controlled trial in chronic schizophrenia.” Brit. J. Psychiat., 109, 531–535.Google Scholar
Matheu, H., and Fogel, E. J. (1961). “Clinical effects of fluphenazine dihydrochloride in chronic schizophrenia.” J. Neuropsychiat., 3, 105–111.Google Scholar
Millar, J. (1963). “A trial of fluphenazine in schizophrenia.” Brit. J. Psychiat., 109, 428–432.CrossRefGoogle Scholar
Reznikoff, L. (1960). “The use of fluphenazine in rehabilitation of chronic schizophrenic patients.” Amer. J. Psychiat., 117, 457.CrossRefGoogle Scholar
Roizin, L., Kaufman, M., and Casselman, B. (1961). “Structural changes induced by neuroleptics.” In: Extrapyramidal System and Neuroleptics, pp. 125–133. Vide supra .Google Scholar
Rouleau, Y., Plante, M., Grantham, H., and Dion, C. (1961). “The clinical evaluation of 7843 R.P. or thioproperazine (Majeptil) in the treatment of psychiatric illnesses.” Laval Med., 32, 563–577.Google Scholar
Rudrauf, J., and Challou, C. (1961). “Etude clinique sur l'action conjuguée de l'orphenadrine et de la thiopropérazine: correction d'impregnation neuroleptique et synergie thérapeutique.” Acta Neurol. et Psychiat. Belg., 61, 103–109.Google Scholar
Sarwer-Foner, G. J. (1961). “Some comments on the psychodynamic aspects of the extrapyramidal reactions.” In: Extrapyramidal System and Neuroleptics, pp. 527–533. Vide supra .Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.